Fidelity Management & Research Company led a $100m Series B round in Galvanize Therapeutics.

Fidelity Management & Research Company, a privately-owned investment manager, led a $100m Series B round in Galvanize Therapeutics, a commercial-stage biomedical platform company operating at the convergence of engineering, biology and healthcare delivery, with participation from Intuitive Surgical, ATP, and Gilmartin Capital. "We are energized by this vote of confidence from our investors in our technology platform and team as we seek to bring transformative electrosurgical therapies to patients worldwide," Jonathan Waldstreicher, Galvanize Therapeutics Founder and CEO.